We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Molecular Pathway Controls Metastasis in Mouse Melanoma Model

By LabMedica International staff writers
Posted on 05 Jan 2015
Print article
Image: Dysregulation of the protein Chi3l1 allows melanoma (black specks) to spread to the lungs of mice. Chi3l1 was relatively unchecked in the lung on the right, compared to the lung on the left, which had much less spread of the cancer (Photo courtesy of Brown University).
Image: Dysregulation of the protein Chi3l1 allows melanoma (black specks) to spread to the lungs of mice. Chi3l1 was relatively unchecked in the lung on the right, compared to the lung on the left, which had much less spread of the cancer (Photo courtesy of Brown University).
Cancer researchers have found that the protein Chi3l1 (Chitinase 3-like-1) stimulates formation of metastases in a mouse model under the regulatory influence of the protein semaphorin 7a (Sema7a) and its receptors.

The CHI3L1 gene encodes a glycoprotein member of the glycosyl hydrolase 18 family. The protein product lacks chitinase activity and is secreted by activated macrophages, chondrocytes, neutrophils, and synovial cells. The protein is thought to play a role in the process of inflammation and tissue remodeling. Semaphorins are a class of secreted and membrane proteins that act as axonal growth cone guidance molecules. They primarily act as short-range inhibitory signals and signal through multimeric receptor complexes with plexins being the major class of semaphorin receptor proteins.

Chi3l1 was found in earlier studies to be induced in cancers where it indicated a poor prognosis. However, it has not been known whether it actually contributed to cancer progression. To address this gap in knowledge investigators at Brown University (Providence, RI, USA) examined the production of Chi3l1 in a mouse model of melanoma lung metastases.

They reported in the December 15, 2014, online edition of the journal Cancer Research that Chi3l1 levels were elevated in mice, as in humans, with progressing cancer. Chi3l1 was induced during pulmonary melanoma metastasis, and this induction was regulated by Sema7a, interacting in stimulatory or inhibitory ways with its beta-1 integrin or Plexin C1 receptors, respectively. In mouse strains with genetic deletions of CHI3L1 or Sema7a, there was a significant reduction in pulmonary metastasis. Furthermore, antiserum raised against Chi3l1 or Sema7a induced the same reduction in metastasis as was produced by genetic deletions. Melanoma lung metastasis was also decreased in the absence of the cytokine IL-13Ralpha2, a recently identified receptor for Chi3l1, consistent with a key role for Chi3l1 in melanoma spread.

"We think everybody has Chitinase 3-like-1 (Chi3l1) in them because it plays a major role in our ability to fight off infections," said senior author Dr. Jack A. Elias, professor of medicine and biological sciences at Brown University. "But one of the things this paper shows is that inducing this molecule seems to be very important in the ability of tumors to spread. That leads us to believe this may be a fundamental pathway in the generation of metastases. We know what molecules are involved in the triggering of this. We do not know where they are and which of them are on the tumor and which are in the normal tissue around the tumor."

Related Links:

Brown University


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Silver Member
Rubella Infection ELISA
ReQuest RUBELLA IgM ELISA Kit
New
Adenovirus Detection Kit
REALQUALITY RQ-ADENO

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.